Trevi Therapeutics, Inc. TRVI Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s effective income tax rate reconciliation nondeductible expense share based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s effective income tax rate reconciliation nondeductible expense share based compensation cost?
- Trevi Therapeutics, Inc. (TRVI) reported effective income tax rate reconciliation nondeductible expense share based compensation cost of -2.8% in Q4 2025.
- What does effective income tax rate reconciliation nondeductible expense share based compensation cost mean?
- This metric measures the percentage impact of nondeductible share-based compensation expenses on the effective income tax rate. It illustrates how equity-based incentive structures affect the company's overall tax reconciliation. High values indicate a significant tax disadvantage associated with the company's compensation strategy.